MCID: ATS007
MIFTS: 61

Autism Spectrum Disorder

Categories: Rare diseases, Mental diseases, Genetic diseases

Aliases & Classifications for Autism Spectrum Disorder

MalaCards integrated aliases for Autism Spectrum Disorder:

Name: Autism Spectrum Disorder 12 53 25 54 43 15
Autism Spectrum Disorders 29 6 73
Asd 53 25
Pervasive Developmental Disorder 25
Pervasive Development Disorder 73
Autistic Continuum 25
Autistic Behavior 73

Classifications:



External Ids:

Disease Ontology 12 DOID:0060041

Summaries for Autism Spectrum Disorder

MedlinePlus : 43 Autism spectrum disorder (ASD) is a neurological and developmental disorder that begins early in childhood and lasts throughout a person's life. It affects how a person acts and interacts with others, communicates, and learns. It includes what used to be known as Asperger syndrome and pervasive developmental disorders. It is called a "spectrum" disorder because people with ASD can have a range of symptoms. People with ASD might have problems talking with you, or they might not look you in the eye when you talk to them. They may also have restricted interests and repetitive behaviors. They may spend a lot of time putting things in order, or they may say the same sentence again and again. They may often seem to be in their "own world." At well-child checkups, the health care provider should check your child's development. If there are signs of ASD, your child will have a comprehensive evaluation. It may include a team of specialists, doing various tests and evaluations to make a diagnosis. The causes of ASD are not known. Research suggests that both genes and environment play important roles. There is currently no one standard treatment for ASD. There are many ways to increase your child's ability to grow and learn new skills. Starting them early can lead to better results. Treatments include behavior and communication therapies, skills training, and medicines to control symptoms. NIH: National Institute of Child Health and Human Development

MalaCards based summary : Autism Spectrum Disorder, also known as autism spectrum disorders, is related to pervasive developmental disorder and autism, and has symptoms including widespread abnormalities of social interactions, severely restricted interests and highly repetitive behavior. An important gene associated with Autism Spectrum Disorder is EHMT1 (Euchromatic Histone Lysine Methyltransferase 1), and among its related pathways/superpathways is miRNAs involved in DNA damage response. The drugs Aripiprazole and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and eye.

Disease Ontology : 12 A pervasive developmental disorder that is a spectrum of psychological conditions. The disease has symptom widespread abnormalities of social interactions and communication, has symptom severely restricted interests and has symptom highly repetitive behavior.

Genetics Home Reference : 25 Autism spectrum disorder (ASD) is a condition that appears very early in childhood development, varies in severity, and is characterized by impaired social skills, communication problems, and repetitive behaviors. These difficulties can interfere with affected individuals' ability to function in social, academic, and employment settings. People with ASD also have an increased risk of psychiatric problems such as anxiety, depression, obsessive-compulsive disorder, and eating disorders.

NIH Rare Diseases : 53 Autism spectrum disorder (ASD) is a condition that affects the development of social and communication skills. It includes features of four conditions which were once thought to be separate syndromes - autistic disorder, Asperger syndrome, childhood disintegrative disorder, and pervasive developmental disorder. Signs and symptoms often become apparent in the first 2-3 years of life and vary significantly from person to person. Common symptoms shared by people with ASD include restrictive and repetitive behaviors, social impairment and communication difficulties. The underlying cause of ASD is generally unknown and it is likely that a variety of factors contribute to the development of the condition. ASD appears to run in some families, suggesting that genetics may play a role in some cases. Although there is no cure for ASD, treatment is available that significantly improves the long-term outlook for affected people. Treatment often includes a combination of techniques such as medications, occupational therapy, speech therapy and physical therapy.

NINDS : 54 Autistic disorder (sometimes called autism or classical ASD) is the most common condition in a group of developmental disorders known as the autism spectrum disorders (ASDs).   Autistic children have difficulties with social interaction, display problems with verbal and nonverbal communication, and exhibit repetitive behaviors or narrow, obsessive interests. These behaviors can range in impact from mild to disabling. Autism varies widely in its severity and symptoms and may go unrecognized, especially in mildly affected children or when more debilitating handicaps mask it. Scientists aren’t certain what causes autism, but it’s likely that both genetics and environment play a role.   Autism spectrum disorder is diagnosed based on symptoms, signs, and other testing according to the Diagnostic and Statistical Manual V, a guide created by the American Psychiatric Association to diagnose mental disorders. Children should be screened for developmental delays during periodic checkups and specifically for autism at 18- and 24-month well child visits.

Wikipedia : 76 Autism spectrum, also known as autism spectrum disorder (ASD), is a range of conditions classified as... more...

Related Diseases for Autism Spectrum Disorder

Diseases in the Autism family:

Autism 5 Autism 8
Autism 3 Autism 6
Autism 7 Autism 11
Autism 12 Autism 13
Autism 9 Autism 10
Autism 15 Autism 16
Autism 17 Autism 18
Autism 19 Autism Spectrum Disorder

Diseases related to Autism Spectrum Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 226, show less)
# Related Disease Score Top Affiliating Genes
1 pervasive developmental disorder 34.1 PTCHD1 RPL10 SHANK2
2 autism 33.2 EHMT1 PTCHD1 RPL10 SHANK2
3 muscular dystrophy, duchenne type 29.8 MIR146B MIR381 MIR432 MIR95
4 adnp-related intellectual disability and autism spectrum disorder 12.3
5 patent foramen ovale 11.9
6 adnp syndrome 11.8
7 arthrogryposis, mental retardation, and seizures 11.6
8 helsmoortel-van der aa syndrome 11.6
9 asperger syndrome 11.6
10 timothy syndrome 11.3
11 fragile x syndrome 11.3
12 specific language impairment 11.2
13 rett syndrome 11.2
14 chromosome 15q13.3 deletion syndrome 11.2
15 speech and communication disorders 11.2
16 16p11.2 duplication 11.2
17 mental retardation, autosomal recessive 38 11.1
18 mental retardation, autosomal dominant 26 11.1
19 autism x-linked 4 11.0
20 epilepsy, familial focal, with variable foci 1 11.0
21 pitt-hopkins syndrome 11.0
22 specific language impairment 5 11.0
23 schaaf-yang syndrome 11.0
24 chromosome 15q11.2 deletion syndrome 11.0
25 neurodevelopmental disorder with or without anomalies of the brain, eye, or heart 11.0
26 childhood disintegrative disease 11.0
27 syngap1-related intellectual disability 11.0
28 autism x-linked 1 10.8
29 autism x-linked 2 10.8
30 autism x-linked 3 10.8
31 autism x-linked 5 10.8
32 autism x-linked 6 10.8
33 chromosome 2q37 deletion syndrome 10.8
34 potocki-shaffer syndrome 10.8
35 athabaskan brainstem dysgenesis syndrome 10.8
36 macrocephaly/autism syndrome 10.8
37 autism 5 10.8
38 autism 8 10.8
39 autism 3 10.8
40 autism 6 10.8
41 autism 7 10.8
42 autism 11 10.8
43 autism 12 10.8
44 potocki-lupski syndrome 10.8
45 autism 13 10.8
46 autism 9 10.8
47 autism 10 10.8
48 autism 15 10.8
49 chromosome 1q21.1 deletion syndrome, 1.35-mb 10.8
50 autism 16 10.8
51 autism 17 10.8
52 chromosome 16p13.3 duplication syndrome 10.8
53 autism 18 10.8
54 white-sutton syndrome 10.8
55 ring chromosome 14 syndrome 10.8
56 luscan-lumish syndrome 10.8
57 epilepsy, familial focal, with variable foci 2 10.8
58 epilepsy, familial focal, with variable foci 3 10.8
59 brachycephaly, trichomegaly, and developmental delay 10.8
60 atypical autism 10.8
61 cask-related disorders 10.8
62 16p11.2 deletion syndrome 10.8
63 autosomal dominant intellectual disability 30 10.8
64 chromosome 3p- syndrome 10.8
65 hivep2-related intellectual disability 10.8
66 scn2a related disorders 10.8
67 syngap1-related non-syndromic intellectual disability 10.8
68 ppp2r5d-related intellectual disability 10.8
69 ovarian serous carcinoma 10.6 MIR23A MIR27A MIR93
70 aging 10.6
71 anxiety 10.5
72 attention deficit-hyperactivity disorder 10.5
73 alacrima, achalasia, and mental retardation syndrome 10.5
74 schizophrenia 10.4
75 nonalcoholic fatty liver disease 10.4 MIR140 MIR27A MIR95
76 pituitary adenoma 10.4 MIR15A MIR212
77 dermatomyositis 10.4 MIR146B MIR148B MIR381
78 epilepsy 10.3
79 global developmental delay, absent or hypoplastic corpus callosum, and dysmorphic facies 10.3
80 depression 10.2
81 ovarian epithelial cancer 10.2 MIR140 MIR432
82 down syndrome 10.2
83 cerebritis 10.2
84 williams-beuren syndrome 10.2
85 dysphasia, familial developmental 10.2
86 developmental dyspraxia 10.2
87 cerebral palsy 10.1
88 developmental coordination disorder 10.1
89 oral squamous cell carcinoma 10.1 MIR140 MIR148B MIR23A MIR27A
90 prader-willi syndrome 10.1
91 cognitive function 1, social 10.1
92 neuronitis 10.1
93 phelan-mcdermid syndrome 10.1
94 tuberous sclerosis 10.1
95 fetal alcohol spectrum disorder 10.0
96 neurofibromatosis, type i 10.0
97 neurofibromatosis, type iv, of riccardi 10.0
98 obsessive-compulsive disorder 10.0
99 tuberous sclerosis 1 10.0
100 oculocerebral syndrome with hypopigmentation 10.0
101 conduct disorder 10.0
102 dyslexia 10.0
103 sleep disorder 10.0
104 learning disability 10.0
105 body mass index quantitative trait locus 1 9.9
106 anorexia nervosa 9.9
107 bipolar disorder 9.9
108 alexithymia 9.9
109 cornelia de lange syndrome 9.9
110 borna disease 9.9
111 rubella 9.9
112 childhood-onset schizophrenia 9.9
113 melanoma 9.9 MIR140 MIR15A MIR27A MIR95
114 angelman syndrome 9.8
115 jacobsen syndrome 9.8
116 kabuki syndrome 1 9.8
117 smith-magenis syndrome 9.8
118 celiac disease 1 9.8
119 smith-lemli-opitz syndrome 9.8
120 opitz gbbb syndrome, type i 9.8
121 propionic acidemia 9.8
122 hyperprolactinemia 9.8
123 brain injury 9.8
124 oppositional defiant disorder 9.8
125 apraxia 9.8
126 ileocolitis 9.8
127 mumps 9.8
128 gender identity disorder 9.8
129 bipolar i disorder 9.8
130 iron metabolism disease 9.8
131 tic disorder 9.8
132 astrocytoma 9.8
133 mood disorder 9.8
134 mutism 9.8
135 pilocytic astrocytoma 9.8
136 infertility 9.8
137 measles 9.8
138 eating disorder 9.8
139 mitochondrial disorders 9.8
140 chiari malformation 9.8
141 congenital cytomegalovirus 9.8
142 elective mutism 9.8
143 hyperacusis 9.8
144 autonomic dysfunction 9.8
145 cytomegalovirus infection 9.8
146 megalencephaly 9.8
147 endotheliitis 9.8
148 early-onset schizophrenia 9.8
149 autoimmune disease 9.7
150 corneal dystrophy, posterior polymorphous, 1 9.7
151 cri-du-chat syndrome 9.7
152 femoral-facial syndrome 9.7
153 gilles de la tourette syndrome 9.7
154 li-fraumeni syndrome 9.7
155 myotonic dystrophy 1 9.7
156 optic nerve hypoplasia, bilateral 9.7
157 parkinson disease, late-onset 9.7
158 rheumatoid arthritis 9.7
159 septooptic dysplasia 9.7
160 strabismus 9.7
161 muckle-wells syndrome 9.7
162 cerebrotendinous xanthomatosis 9.7
163 charge syndrome 9.7
164 costello syndrome 9.7
165 hyperlexia 9.7
166 succinic semialdehyde dehydrogenase deficiency 9.7
167 cerebral creatine deficiency syndrome 1 9.7
168 asthma 9.7
169 nicolaides-baraitser syndrome 9.7
170 xanthomatosis 9.7
171 epileptic encephalopathy, early infantile, 6 9.7
172 autoimmune disease 1 9.7
173 nablus mask-like facial syndrome 9.7
174 li-fraumeni syndrome 2 9.7
175 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 9.7
176 chromosome 2p16.1-p15 deletion syndrome 9.7
177 trichotillomania 9.7
178 witteveen-kolk syndrome 9.7
179 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 9.7
180 arthritis 9.7
181 lennox-gastaut syndrome 9.7
182 inflammatory bowel disease 9.7
183 syndromic intellectual disability 9.7
184 body dysmorphic disorder 9.7
185 chromosome 15q24 deletion syndrome 9.7
186 osteomyelitis 9.7
187 pre-eclampsia 9.7
188 microphthalmia 9.7
189 separation anxiety disorder 9.7
190 hyperandrogenism 9.7
191 lyme disease 9.7
192 paranoid schizophrenia 9.7
193 eclampsia 9.7
194 amenorrhea 9.7
195 leopard syndrome 9.7
196 constipation 9.7
197 neonatal jaundice 9.7
198 psychotic disorder 9.7
199 corneal dystrophy 9.7
200 antiphospholipid syndrome 9.7
201 gingivitis 9.7
202 superior mesenteric artery syndrome 9.7
203 placental insufficiency 9.7
204 echolalia 9.7
205 juvenile pilocytic astrocytoma 9.7
206 mitochondrial metabolism disease 9.7
207 axonal neuropathy 9.7
208 neuropathy 9.7
209 muscular dystrophy 9.7
210 myotonic dystrophy 9.7
211 7q11.23 duplication syndrome 9.7
212 dystrophinopathies 9.7
213 mbd5 haploinsufficiency 9.7
214 47, xxy 9.7
215 cerebral folate deficiency 9.7
216 chromosome xp deletion 9.7
217 congenital rubella 9.7
218 myotonia atrophica 9.7
219 tetrasomy 9p 9.7
220 wells syndrome 9.7
221 dysautonomia 9.7
222 encephalopathy 9.7
223 seizure disorder 9.7
224 spasticity 9.7
225 distal trisomy 10q 9.7
226 hepatocellular carcinoma 9.6 MIR148B MIR15A MIR212 MIR23A MIR27A MIR93

Graphical network of the top 20 diseases related to Autism Spectrum Disorder:



Diseases related to Autism Spectrum Disorder

Symptoms & Phenotypes for Autism Spectrum Disorder

Symptoms:

12 (showing 3, show less)
  • widespread abnormalities of social interactions
  • severely restricted interests
  • highly repetitive behavior

UMLS symptoms related to Autism Spectrum Disorder:


sleep disturbances, photophobia, personality changes, restlessness, pseudobulbar behavioral symptoms

Drugs & Therapeutics for Autism Spectrum Disorder

Drugs for Autism Spectrum Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 286, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 2 129722-12-9 60795
2
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-61-6, 62-31-7 681
3
Methylphenidate Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 113-45-1 4158
4
Oxytocin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-56-6 439302 53477758
5
Memantine Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable 19982-08-2 4054
6
Guanfacine Approved, Investigational Phase 4,Not Applicable 29110-47-2 3519
7
Milnacipran Approved, Investigational Phase 4 92623-85-3 65833
8
Acetylcysteine Approved, Investigational Phase 4,Phase 2 616-91-1 12035
9
Metformin Approved Phase 4,Phase 3 657-24-9 14219 4091
10
Olanzapine Approved, Investigational Phase 4,Phase 2 132539-06-1 4585
11
Risperidone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 106266-06-2 5073
12
Ziprasidone Approved Phase 4,Phase 3,Phase 2 146939-27-7 60854
13
Acetylcholine Approved Phase 4,Phase 1 51-84-3 187
14
Donepezil Approved Phase 4,Phase 1,Phase 2 120014-06-4 3152
15
Melatonin Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 73-31-4 896
16
Choline Approved, Nutraceutical Phase 4 62-49-7 305
17 Antipsychotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Central Nervous System Depressants Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
19 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
20 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Antibodies Phase 4
23 gamma-Globulins Phase 4
24 Immunoglobulins Phase 4
25 Immunoglobulins, Intravenous Phase 4
26 Rho(D) Immune Globulin Phase 4
27 Antiparkinson Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
28 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
29 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
30 Central Nervous System Stimulants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Dopamine Uptake Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
32 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Antioxidants Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
35 Antiviral Agents Phase 4,Phase 2
36 Protective Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
37 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2
38 Oxytocics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
39 Excitatory Amino Acid Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
40 Excitatory Amino Acids Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
41 Adrenergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
42 Adrenergic Agonists Phase 4,Phase 2,Not Applicable
43 Adrenergic alpha-2 Receptor Agonists Phase 4,Phase 2,Not Applicable
44 Adrenergic alpha-Agonists Phase 4,Phase 2,Not Applicable
45 Antihypertensive Agents Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
46 Atomoxetine Hydrochloride Phase 4,Phase 3
47 Antidepressive Agents Phase 4,Phase 3,Phase 2,Phase 1
48 Serotonin Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Serotonin Uptake Inhibitors Phase 4,Phase 2,Phase 1
50 Antidotes Phase 4,Phase 2
51 Expectorants Phase 4,Phase 2
52 N-monoacetylcystine Phase 4,Phase 2
53 Respiratory System Agents Phase 4,Phase 2,Phase 3
54 Hypoglycemic Agents Phase 4,Phase 3,Phase 2
55 Antiemetics Phase 4,Phase 2
56 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
57 Dopamine Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
58 Gastrointestinal Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
59 insulin Phase 4,Phase 2
60 Insulin, Globin Zinc Phase 4,Phase 2
61 Serotonin Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
62 Antimetabolites Phase 4,Phase 3
63 Cholinergic Agents Phase 4,Phase 3,Phase 2,Phase 1
64 Cholinesterase Inhibitors Phase 4,Phase 3,Phase 1,Phase 2
65 Nootropic Agents Phase 4,Phase 3,Phase 1,Phase 2
66 Vasodilator Agents Phase 4,Not Applicable,Early Phase 1
67 Hypolipidemic Agents Phase 4
68 Lipid Regulating Agents Phase 4
69 Lisdexamfetamine Dimesylate Phase 4
70 Omega 3 Fatty Acid Nutraceutical Phase 4,Phase 2,Not Applicable
71
Serotonin Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-67-9 5202
72 cysteine Nutraceutical Phase 4,Phase 2
73
Adenosine Approved, Investigational Phase 3,Phase 2,Not Applicable 58-61-7 60961
74
Benzocaine Approved, Investigational Phase 2, Phase 3,Phase 1,Not Applicable 1994-09-7, 94-09-7 2337
75
Riluzole Approved, Investigational Phase 2, Phase 3 1744-22-5 5070
76
Cycloserine Approved Phase 3 68-41-7 401 6234
77
Acamprosate Approved, Investigational Phase 3,Phase 2 77337-76-9 71158
78
Ethanol Approved Phase 3,Phase 2,Not Applicable 64-17-5 702
79
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
80
Hydroxocobalamin Approved Phase 2, Phase 3 13422-51-0 11953898 44475014
81
Galantamine Approved Phase 3 357-70-0 9651
82
Secretin Approved, Investigational Phase 3 108153-74-8
83
Bisacodyl Approved Phase 3,Not Applicable 603-50-9
84
Dextromethorphan Approved Phase 2, Phase 3 125-71-3 5360696 5362449
85
Guaifenesin Approved, Investigational, Vet_approved Phase 2, Phase 3 93-14-1 3516
86
Metronidazole Approved Phase 2, Phase 3 443-48-1 4173
87
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
88
Mianserin Approved, Investigational Phase 3 24219-97-4 4184
89
Mirtazapine Approved Phase 3 85650-52-8, 61337-67-5 4205
90 Atosiban Approved, Investigational Phase 3 90779-69-4
91
Vitamin D Approved, Nutraceutical, Vet_approved Phase 2, Phase 3,Not Applicable 1406-16-2
92 tannic acid Approved, Nutraceutical Phase 2, Phase 3,Phase 1,Not Applicable
93
Ergocalciferol Approved, Nutraceutical Phase 2, Phase 3,Not Applicable 50-14-6 5280793
94
Cyanocobalamin Approved, Nutraceutical Phase 2, Phase 3 68-19-9 44176380
95
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3,Phase 1,Not Applicable 59-30-3 6037
96
Methylcobalamin Approved, Experimental, Investigational, Nutraceutical Phase 2, Phase 3 13422-55-4
97 Vitamins Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
98 Hormone Antagonists Phase 3,Phase 2,Not Applicable
99 Hormones Phase 3,Phase 2,Not Applicable
100 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Not Applicable
101 Anticonvulsants Phase 2, Phase 3
102 Neuroprotective Agents Phase 2, Phase 3
103 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
104 Antibiotics, Antitubercular Phase 3,Phase 1,Phase 2
105 Antitubercular Agents Phase 3
106 Renal Agents Phase 3
107 triamcinolone acetonide Phase 3
108 Triamcinolone diacetate Phase 3
109 Triamcinolone hexacetonide Phase 3
110 Fluorodeoxyglucose F18 Phase 3
111 Bone Density Conservation Agents Phase 2, Phase 3,Not Applicable
112 Ergocalciferols Phase 2, Phase 3,Not Applicable
113 Micronutrients Phase 2, Phase 3,Phase 3,Phase 1,Early Phase 1,Not Applicable
114 Trace Elements Phase 2, Phase 3,Phase 3,Phase 1,Early Phase 1,Not Applicable
115 Vitamin B 12 Phase 2, Phase 3
116 Vitamin B Complex Phase 2, Phase 3,Phase 1,Not Applicable
117 Dopamine D2 Receptor Antagonists Phase 3,Phase 2,Phase 1
118 Paliperidone Palmitate Phase 3
119 Serotonin 5-HT2 Receptor Antagonists Phase 3,Phase 2,Phase 1
120 Adrenergic alpha-Antagonists Phase 3,Phase 2,Phase 1
121 Adrenergic Antagonists Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
122
Lurasidone hydrochloride Phase 3,Phase 2,Phase 1 367514-87-2 213046
123 Antidepressive Agents, Second-Generation Phase 3,Phase 2,Phase 1
124 Hematinics Phase 3,Phase 2
125 Tocolytic Agents Phase 3,Phase 2
126 Vasoconstrictor Agents Phase 3,Phase 2,Phase 1,Early Phase 1
127 Antiparasitic Agents Phase 2, Phase 3,Phase 1
128 Antiprotozoal Agents Phase 2, Phase 3,Phase 1
129 Antitussive Agents Phase 2, Phase 3
130 Chlorpheniramine, phenylpropanolamine drug combination Phase 2, Phase 3
131 Antidepressive Agents, Tricyclic Phase 3
132 Histamine Antagonists Phase 3
133 Histamine H1 Antagonists Phase 3
134
Histamine Phosphate Phase 3 51-74-1 65513
135 Epoetin alfa Phase 3 113427-24-0
136 Vasotocin Phase 3
137 Calciferol Nutraceutical Phase 2, Phase 3,Not Applicable
138 Vitamin D2 Nutraceutical Phase 2, Phase 3,Not Applicable
139
Cobalamin Nutraceutical Phase 2, Phase 3 13408-78-1 6438156
140 Folate Nutraceutical Phase 2, Phase 3,Phase 1,Not Applicable
141 Vitamin B12 Nutraceutical Phase 2, Phase 3
142 Vitamin B9 Nutraceutical Phase 2, Phase 3,Phase 1,Not Applicable
143
Naltrexone Approved, Investigational, Vet_approved Phase 1, Phase 2 16590-41-3 5360515
144
Amantadine Approved Phase 2 768-94-5 2130
145
Miconazole Approved, Investigational, Vet_approved Phase 2,Not Applicable 22916-47-8 4189
146
Iron Approved Phase 2 7439-89-6 23925
147
Baclofen Approved Phase 2,Phase 1,Not Applicable 1134-47-0 2284
148
Pioglitazone Approved, Investigational Phase 2 111025-46-8 4829
149
Suramin Approved, Investigational Phase 1, Phase 2 145-63-1 5361
150
Lenalidomide Approved Phase 2 191732-72-6 216326
151
Omeprazole Approved, Investigational, Vet_approved Phase 1, Phase 2 73590-58-6 4594
152
Vancomycin Approved Phase 1, Phase 2,Phase 2 1404-90-6 441141 14969
153
Citalopram Approved Phase 2,Phase 1 59729-33-8 2771
154
Quinidine Approved, Investigational Phase 2 56-54-2 441074
155
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 2 7487-88-9 24083
156
Zinc Approved, Investigational Phase 2,Phase 1 7440-66-6 23994
157
Everolimus Approved Phase 2 159351-69-6 6442177
158
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
159
Sertraline Approved Phase 2 79617-96-2 68617
160
Levoleucovorin Approved, Investigational Phase 2 68538-85-2
161
Coal tar Approved Phase 2 8007-45-2
162
Amphetamine Approved, Illicit, Investigational Phase 2 300-62-9 5826 3007
163
Buspirone Approved, Investigational Phase 2,Not Applicable 36505-84-7 2477
164
Dronabinol Approved, Illicit Phase 2 1972-08-3 16078
165
Bumetanide Approved Phase 2 28395-03-1 2471
166 Orange Approved, Nutraceutical Phase 2,Not Applicable
167
Glutamic Acid